Ventria Bioscience Appoints Seymour Fein, M.D. as Chief Medical Officer
FORT COLLINS, Colo.--(BUSINESS WIRE)--Ventria Bioscience announced today that Seymour Fein, M.D., has been appointed as the company’s new Chief Medical Officer. Dr. Fein will be responsible for the company’s clinical development and medical affairs functions.
“The expansion of our clinical development capabilities was a necessary and significant step for Ventria Bioscience as our therapeutic product-development pipeline advances”
“The expansion of our clinical development capabilities was a necessary and significant step for Ventria Bioscience as our therapeutic product-development pipeline advances,” said Scott Deeter, president and chief executive officer of Ventria Bioscience. “Dr. Fein will oversee our current clinical pipeline and drive future product development, clinical study design, and budgets so that Ventria Bioscience’s products meet the medical needs of patients and lead to commercial success.”
Dr. Fein began his career at Hoffmann-La Roche Ltd. as a senior research physician and was responsible for a clinical development program that led to U.S. Food and Drug Administration (FDA) approval of recombinant interferon-alpha for cancer treatment. Dr. Fein was also the medical director of Bayer Healthcare Pharmaceuticals (U.S.) where he was responsible for therapeutic areas including gastroenterology, oncology, and cariology. He later served as medical director for Rorer Group (now part of Sanofi) and Ohmeda (now part of Baxter). Dr. Fein founded and has been managing partner of a clinical and regulatory consulting organization and has worked closely with the Division of Gastroenterology and Inborn Errors Products at the FDA. He has participated in the development of and FDA approval of numerous drug products in many therapeutic areas. Dr. Fein has successfully overseen entrepreneurial drug development leading to the FDA approval of two orphan drug products in the field of gastroenterology.
Dr. Fein received his B.A. degree from the University of Pennsylvania and his M.D. degree with honors from New York Medical College. He completed a three-year residency in internal medicine at Dartmouth and a three-year fellowship in medical oncology and hematology at Harvard Medical School, where he served as an instructor of medicine during his final fellowship year. Dr. Fein is board-certified in both oncology and internal medicine.
About Ventria Bioscience
Ventria Bioscience is a biopharmaceutical company with a product pipeline targeting unmet medical needs in gastroenterology. Ventria Bioscience’s patented ExpressTec biomanufacturing technology enables the development of new and cost-effective biologic products. For more information, visit www.Ventria.com.